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Abstract: Despite the constantly updated knowledge regarding the alterations occurring in the
cells of patients with psoriasis, the status and the role of the lysosome, a control center of cell
metabolism, remain to be elucidated. The architecture of the epidermis is largely regulated
by the action of lysosomes, possibly activating signaling pathways in the cellular crosstalk of
keratinocytes—epidermal cells—with infiltrating immune cells. Thus, in the present study, lysosome
alterations were examined in vitro and in situ using a two-dimensional (2D) keratinocyte model of
HaCaT cells with “psoriasis-like” inflammation and skin specimens, respectively. Specific fluorescence
and immunohistochemical staining showed an augmented level of acidic organelles in response to
keratinocyte activation (mimicking a psoriatic condition while maintaining the membrane integrity of
these structures) as compared with the control, similar to that seen in skin samples taken from patients.
Interestingly, patients with the most pronounced PASI (Psoriasis Area and Severity Index), BSA
(Body Surface Area), and DLQI (Dermatology Life Quality Index) scores suffered a high incidence of
positive lysosomal-associated membrane protein 1 (LAMP1) expression. Moreover, it was found that
the gene deregulation pattern was comparable in lesioned (PP) and non-lesioned (PN) patient-derived
skin tissue, which may indicate that these alterations occur prior to the onset of the characteristic
phenotype of the disease. Changes in the activity of genes encoding the microphthalmia family
(MiT family) of transcription factors and mammalian target of rapamycin complex 1 (MTORC1) were
also observed in the in vitro psoriasis model, indicating that the biogenesis pathway of this arm is
inhibited. Interestingly, in contrast to the keratinocytes of HaCaT with “psoriasis-like” inflammation,
LAMP1 was up-regulated in both PP and PN skin, which can be a potential sign of an alternative
mechanism of lysosome formation. Defining the molecular profile of psoriasis in the context of “the
awesome lysosome” is not only interesting, but also desired; therefore, it is believed that this paper
will serve to encourage other researchers to conduct further studies on this subject.
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1. Introduction
In recent years, increasing attention has been paid to the contribution of lysosomes to autoimmune
diseases [1,2]. Of all the cellular components, the lysosome is an obvious candidate to play a role
in the inflammatory process [3]. The relatively recent, intensively developing field of “lysosomics”
provides a range of important information regarding the role of lysosomes in the inflammatory response
and autoimmune conditions [4–7], despite the fact that the first signs of lysosomal involvement in
inflammatory diseases were identified decades ago [8]. Unfortunately, these investigations were
only superficially concerned with inflammatory skin diseases, including the most common human
skin autoimmune disease, psoriasis (PsO) [9–12]. PsO, considered to develop through the crosstalk
between the epidermal keratinocytes and immunocytes, is a polygenic, chronic, inflammatory skin
disease affecting approximately 2−3% of the population worldwide. It is characterized by keratinocyte
hyperproliferation, abnormal epidermal differentiation, and infiltration of immune cells into lesions [13].
Research carried out in the 1960’s highlighted the differences in the presence of lysosomes in the
keratinocytes of psoriatic skin in relation to healthy skin [14]. Several subsequent studies have
shown that affected psoriatic skin differs from normal skin with respect to the level of activity of
lysosomal hydrolytic enzymes and membrane proteins [15–18]. Nevertheless, the outcomes of these
studies are generally contradictory, since both increases and decreases in the activity of these enzymes
were observed [18]. It should be mentioned, however, that this phenomenon was determined in
various tissues and cells such as skin, scales covering psoriatic papules, lymphocytes, granulocytes,
neutrophils, and blood serum, which could have led to these discrepancies. The observations have
become increasingly widespread, since multiple studies have reported on the manner by which disruption
of normal lysosomal function leads to abnormalities in inflammation and immunity [1,6,18–20]. The link
between lysosomes and skin inflammation was established by studies conducted in the 1970’s [21–23].
Inflammation in skin diseases, such as PsO, is regulated by a complex network of keratinocytes and
immune cells that infiltrate the epidermis [24]. Understanding of the lysosome signaling in the immune
response is still in its infancy, same as knowledge of the potential involvement of lysosomes and lysosomal
compartments in the inflammatory signaling network in respect to inflammatory skin diseases is residual.
The question is, how can we move forward to gain further information and a greater understanding
of this issue. To carry out studies assessing the potential contribution of lysosomes to the disturbed
processes of apoptosis and autophagy, abnormalities of sphingolipid and ceramide metabolism pathways,
incorrect presentation of antigens by major histocompatibility complex (MHC) class I and II molecules or
increased transcription of genes encoding selected proinflammatory cytokines and chemokines—processes
being deregulated in this dermatosis, the gaps in knowledge must be filled using recently developed
“lysosomics”, therein in relevance to psoriasis. Hence, in vitro and in situ study of the pattern of
the lysosomal system, a potential target for therapeutic intervention in human autoimmune-mediated
inflammatory skin diseases, was the focus of the present research report. In addition to the human
immortalized keratinocyte HaCaT model, skin tissue from biopsies of controls, healthy individuals, and
patients with psoriasis, from the involved and noninvolved psoriatic skin, were evaluated.
2. Results
2.1. Alterations in the Extent of Lysosomal Compartments and Other Acidic Vesicles in Response to
Keratinocyte Activation, Mimicking Psoriatic Condition
Firstly, quantitative assessment and distribution of acidic cell compartments, lysosomal
membrane permeabilization, and maintenance of the intracellular (lysosomal–cytosolic) pH gradient
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in proinflammatory cytokine- and vehicle-treated HaCaT keratinocytes was performed. To maintain
the cells in an undifferentiated state, thus imitating as much as possible a “psoriasis-like” inflammation
status of HaCaT cells, the calcium ion concentration in the culture medium (Ca2+ lower than or equal
to 0.1 mM) was decreased. Moreover, supplementary control assays were conducted by the addition
of 2 mM calcium chloride to best mimic the differentiated keratinocyte phenotype, thus reflecting
the normal state of skin health. The characteristics were evaluated by fluorescent microscopy using
LysoTracker Red DND-99 (Figure 1A), an antibody against lysosomal-associated membrane protein 1
(anti-LAMP1) also known as lysosome-associated membrane glycoprotein 1 and CD107a (Cluster of
Differentiation 107a) (Figure 1A), as well as with acridine orange (AO) (Figure 1B1,B2). Cells were
divided into four groups from the same passage and cultured respectively as: (i) Keratinocytes of
HaCaT with “psoriasis-like” inflammation with the addition of a combination of proinflammatory
cytokines (“cytokine mix”): interleukin 1 alpha (IL-1α), interleukin 17A (IL-17A), interleukin 22 (IL-22),
oncostatin M (OSM), and tumor necrosis factor alpha (TNF-α) (2 ng/mL each) in medium containing
Ca2+ ≤0.1 mM; (ii) non-activated keratinocytes in medium containing Ca2+ ≤ 0.1 mM; (iii) keratinocytes
of HaCaT with “psoriasis-like” inflammation with the addition of proinflammatory “cytokine mix” (as
above) in medium containing 2 mM Ca2+; and (iv) non-activated keratinocytes in medium containing
2 mM Ca2+. Control with chloroquine (CQ) was used to increase the number of lysosomes in general
(CQ blocks combining the lysosomes with autophagosomes). In general, the data clearly demonstrate
that there was an increase in the quantity of lysosomes (LAMP1) with a reduction in the total amount
of acidic vesicular structures (LysoTracker Red), while maintaining the membrane integrity of these
structures (AO), in the keratinocytes of HaCaT with “psoriasis-like” inflammation as compared with
the non-activated keratinocytes with a differentiated phenotype (2 mM Ca2+). A similar pattern is
observed in the CQ control cell cultures for all conditions.
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Figure 1. Fluorescence microscopy analysis of lysosomal compartments and other acidic vesicles in 
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“cytokine mix”: interleukin 1 alpha (IL-1α), IL-17A, IL-22, oncostatin M (OSM), and tumor necrosis 
factor alpha (TNF-α) at a concentration of 2 ng/mL each constituent and cultured in medium 
containing Ca2+ ≤ 0.1 mM; (ii) non-activated HaCaT cell control cultured in medium containing Ca2+ ≤ 
0.1 mM; (iii) “cytokine mix”-activated HaCaT cells cultured in medium containing 2 mM Ca2+; and 
(iv) non-activated HaCaT cell control cultured in medium containing 2 mM Ca2+. Control with 
chloroquine (CQ) was used to increase the total amount of lysosomes. All images were captured from 
randomly selected ten microscopic fields containing 50–100 cells, each from three independent 
experiments (n = 3), using a fluorescence microscope. Scale bar represents 0.25 µm. (A) LysoTracker 
Red DND-99 staining showing the distribution of acidic organelles, including mature lysosomes and 
lysosomal-associated membrane protein 1 (LAMP1) staining of the lysosomal membrane. (B1) 
Lysosomal membrane permeabilization detection and visualization of acidic vesicles (AVOs) loaded 
with acridine orange (AO). DNA and RNA are stained green by acridine orange and healthy 
lysosomes are stained red. Upon exposure to chloroquine (positive control for lysosomal membrane 
permeabilization), lysosomes increase in size and stain green and yellow, indicating lysosomal 
swelling. (B2) Acridine orange assay measuring fluorescence intensity emission at 530 and 620 nm 
following excitation at a wavelength of 490 nm. The 530/620 nm ratio indicates cytoplasm to acidic 
vesicle rate. Each treatment was performed in 20 wells. Data represent the mean values ± standard 
deviation (SD) from n = 3. 
Figure 1. Fluorescence icroscopy analysis of lysosomal compartments and other acidic vesicles
in keratinocytes. Shown are representative microscopy images of HaCaT cells: (i) Activated with
“cytokine mix”: interleukin 1 alpha (IL-1α), IL-17A, IL-22, oncostatin M (OSM), and tumor necrosis
factor alpha (TNF-α) at a concentration of 2 ng/mL each constituent and cultured in medium containing
Ca2+ ≤ 0.1 mM; (ii) non-activated HaCaT cell control cultured in medium containing Ca2+ ≤ 0.1
mM; (iii) “cytokine mix”-activated HaCaT cells cultured in medium containing 2 mM Ca2+; and (iv)
non-activated HaCaT cell control cultured in medium containing 2 mM Ca2+. Control with chloroquine
(CQ) was used to increase the total amount of lysosomes. All images were captured from randomly
selected ten microscopic fields containing 50–100 cells, each from three independent experiments (n = 3),
using a fluorescence microscope. Scale bar represents 0.25 µm. (A) LysoTracker Red DND-99 staining
showing the distribution of acidic organelles, including mature lysosomes and lysosomal-associated
membrane protein 1 (LAMP1) staining of the lysosomal membrane. (B1) Lysosomal membrane
permeabilization detection and visualization of acidic vesicles (AVOs) loaded with acridine orange
(AO). DNA and RNA are stained green by acridine orange and healthy lysosomes are stained red.
Upon exposure to chloroquine (positive control for lysosomal membrane permeabilization), lysosomes
increase in size and stain green and yellow, indicating lysosomal swelling. (B2) Acridine orange assay
measuring fluorescence intensity emission at 530 and 620 nm following excitation at a wavelength of
490 nm. The 530/620 nm ratio indicates cytoplasm to acidic vesicle rate. Each treatment was performed
in 20 wells. Data represent the mean values ± standard deviation (SD) from n = 3.
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2.2. No Translocation of Endogenous Transcription factor EB (TFEB) to Nucleus in Keratinocyte Model of
HaCaT Cells with “Psoriasis-Like” Inflammation
The results described above prompted examination of the alterations in the subcellular localization
of endogenous TFEB, a master regulator of lysosome biogenesis and function. Among the acidic
vesicles, the number of lysosomal compartments increased quantitatively in condition which mimics
the psoriatic status, i.e., in response to keratinocyte activation. To test the potential role of
TFEB-mediated lysosomal arrangement in the “psoriasis-like” inflammation phenotype of keratinocytes,
TFEB cytoplasm-to-nucleus shuttling under proinflammatory cytokine-activated and non-activated
conditions was evaluated in in vitro HaCaT cultures. Additional control assays were conducted with
cells cultured in medium containing a high concentration of Ca2+ (2 mM). Interestingly, it was noted
that in keratinocytes grown in medium containing a low concentration of calcium (Ca2+ ≤ 0.1), TFEB
translocated from a diffuse cytoplasmic location to the nucleus, at a level comparable to the selective
inhibitor of mammalian target of rapamycin (mTOR) kinase (Torin 1) positive control, regardless
of whether the keratinocytes were activated psoriatically. Such an effect was not seen when the
keratinocytes were cultured in medium containing a high concentration of calcium ions (Figure 2).
Therefore, it was concluded that the calcium ions, rather than “cytokine-mix” stimulation, was
responsible for this phenomenon.
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Figure 2. Immunofluorescence examination of endogenous transcription factor EB (TFEB) localization
in: (i) HaCaT cells activated with “cytokine mix” and cultured in medium containing Ca2+ ≤ 0.1 mM;
(ii) non-activated keratinocyte control cultured in medium containing Ca2+ ≤ 0.1 mM; (iii) “cytokine
mix”-activated HaCaT cells cultured in medium containing 2 mM Ca2+; and (iv) non-activated
keratinocyte control cultured in medium containing 2 mM Ca2+. Representative microscopy images
from randomly selected ten microscopic fields containing 50–100 cells, each from three independent
experiments (n = 3) of the tested keratinocyte cultures demonstrate the level of TFEB translocation
from the cytoplasm to the nucleus. Scale bar represents 0.25 µm.
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2.3. Acidic Vesicles Ultrastructure Changes in Keratinocyte Model of HaCaT Cells with
“Psoriasis-Like” Inflammation
Intracellular structures, such as lysosomes and lysosome-related organelles (LROs), have a
particular morphological signature that can only be appreciated by ultrastructural analysis at the
electron microscopy level. The patterns undergo various modifications as a result of the action of
various factors, including those linked to the occurrence of a specific disease. In the case of psoriasis,
an in vitro model of keratinocytes that mimics the disease state by stimulation with a combination of
proinflammatory factors in culture medium with a decreased calcium concentration was implemented.
To accomplish the evaluation of the ultrastructure of both proinflammatory cytokine-treated and
non-activated control HaCaT cells, transmission electron microscopy (TEM)-enabled visualization
of representative acidic vesicle structures was performed. As shown in Figure 3, lysosomes (L),
autophagosomal vacuoles (AV), lamellar bodies (LB), carbohydrate-storing lysosomes (LC), lysosomes
of amorphous flocculent and electron dense structure (LD), and large vacuoles (V) could be depicted
by TEM, which were predominant among the acidophilic organelles. In the control samples, the
entire spectrum of autophagosomes and autolysosomes could be seen, whereas in the “psoriasis-like”
sample, there were few autolysosomes and a dominance of autophagosomes with characteristic
double-layered membranes in the form of multilamellar structures, somewhat similar to onion bodies,
which were categorized as LROs. In addition, many more electron-lucent structures were seen in
non-activated cells as compared with those activated with proinflammatory cytokines. Lastly, the
keratinocytes in both experimental groups contained clusters of cellular compartments, mainly in the
perinuclear area, as well as huge lysosome-like vacuoles (giant lysosomes) filled with small structures
resembling mitochondria.
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2.4. Increase of LAMP1 Expression in Psoriatic-Lesioned Skin
To confirm the alterations observed on the in vitro material, analyzes were performed also
on the in vivo material, i.e., skin biopsies. Patients’ clinical data are summarized in Table 1.
Immunohistochemical staining of LAMP1 in skin sections shows its expression in cells of the epidermis
and dermis (Figure 4). It is worth noting that, irrespective of the sample type (PP—psoriatic plaque;
PN—psoriatic normal; and NN—non-psoriatic normal), there were more LAMP1-positive cells in the
epidermis s compared with the dermis (Figure 4A). In turn, in the epidermis, LAMP1 was mainly
present in the basal layer; although, in the case of PP tissue sections from patients nos. 6 and 7, the
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LAMP1-positive cells were in the suprabasal layer, which is further in its spinous portion. In addition,
it was rather simple to quantitate the LAMP1 signal in order to elucidate that the PP specimens had a
greater number of LAMP1-positive cells as compared with those in the PN and NN skin sections, even
though there were differences in the expression of this transmembrane glycoprotein among the skin
samples from the tested individuals (Figure 4B). Comparison of the highest LAMP1 signal, obtained
for PP and PN from patient no. 6, with the lowest, from patient no. 1, showed an increase of 4.6- and
4.1-fold, respectively (Table 2).
Immunohistochemical visualization of LAMP1 allowed the conclusion of a statistically significant
increase in LAMP1 expression, and thus, a statistically important rise in the number of lysosomes in
psoriatic lesions (PP) as compared with non-lesions (PN) in five (patients nos. 1, 2, 3, 6, and 7) among
the seven tested patients. In addition, in four patients (nos. 2, 3, 6, and 7), there was a statistically
significant greater number of lysosomes in PP as compared with NN (i.e., four individuals from the
healthy control group), while in two patients (nos. 1 and 6), there was a statistically significant change
(a reduction and an increase) in the number of lysosomes in PN as compared with NN.
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Figure 4. Immunohistochemical analysis of skin sections stained with an antibody against the lysosomal
marker LAMP1 (lysosomal-associated membrane protein 1). (A) Representative images of LAMP1
staining of skin biopsies (black) from randomly selected six to eight microscopic fields, indicating
the size and number of the lysosomal compartment. CTRL—IgG control for antibody specificity;
PP—psoriatic plaque, PN—psoriatic normal, and NN—non-psoriatic normal. Scale bar represents
20µm. (B) Quantitation of the mean LAMP1 staining in skin biopsies is expressed in arbitrary units.
6 to 8 low power fields of view for each sections were quantified. The horizontal lines show the 95th
percentile bootstrap confidence intervals. Comparisons amo g particular paired PP vs. PN, PP vs.
mean NN, and PN vs. mean NN were performed, and statistical differe ces are observed following
application of a nonparametric Mann-Wh t ey U est, with continuity correction (p≤ 0.05). The asterisks
designate a statistically significant difference between the PP and PN groups, while † and ‡ indicate a
significant difference between the PN and NN, and PP and NN groups, respectively.
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Table 1. Patients’ clinical data including the PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), DLQI (Dermatology Life Quality Index), size of
psoriatic plaque, thickness of psoriatic plaque, type of psoriasis, pruritus, arthralgia, psoriatic arthritis, treatment regimes, comorbidities, gender, and age.
Patient
No.
PASI
(0–72)
BSA
(0–100%)
DLQI
(0–30)
Size of
Psoriatic Plaque
(0: small <3 cm,
1: big >3 cm)
Thickness of
Psoriatic Plaque
(0: thin <0.75 mm,
1: thick >0.75 mm)
Type of Psoriasis
(1: <40 yrs.;
2: >40 yrs.)
Pruritus
(0: no,
1: mild,
2: modest,
3: severe)
Arthralgia
(0: no,
1: yes)
Psoriatic
Arthritis
(0: no,1: yes)
Treatment
Regimes Comorbidities
Gender/
Age
1 3.3 15 5 1 1 2 2 1 0 Topicaltreatment - M/68
2 3.6 13 3 1 1 1 1 0 0 Cyclosporine,PUVA
Hypothyroidism,
insulin resistance M/43
3 5.1 10 6 1 1 2 1 1 1 Topicaltreatment
Diabetes,
hypothyroidism M/51
4 7.2 4 20 0 0 1 3 0 0 Topicaltreatment - F/36
5 8.2 8 12 1 1 1 3 1 0 Topicaltreatment - F/27
6 9.6 21 19 1 1 2 2 0 0 Topicaltreatment
Diabetes,
hypothyroidism,
neurosis nonalcoholic
steatohepatitis obesity
F/61
7 13.2 13 16 1 1 1 2 1 0 Topicaltreatment - F/35
8 1.8 4 8 0 0 1 0 0 0 - - M/26
9 9.6 24 12 1 1 1 3 1 1 Methotrexate
Chronic obstructive
pulmonary disease,
hypertension
M/60
10 23.4 46 13 1 1 1 2 0 0 - - M/25
11 9.3 7 20 0 1 1 3 1 1 - - F/25
12 5 5 4 0 0 1 1 0 0 - Dermatitisherpetiformis, diabetes F/40
13 6.1 4 14 1 1 2 3 1 0 - Coronary disease,diabetes M/64
14 4.4 5 3 1 1 1 2 1 0 - Hypertension F/65
15 3.8 7 4 1 0 1 3 1 0 - - M/26
16 10.3 15 5 1 1 1 1 0 0 - - M/52
17 4.3 5 9 0 0 1 3 0 0 - Epilepsy F/29
18 7.6 19 4 1 1 1 1 0 0 - Glaucoma,hypothyroidism F/81
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Table 2. Quantitation of the lysosomal-associated membrane protein 1 (LAMP1) marker in PP—psoriatic
plaque and PN—psoriatic normal skin (in patients 1 to 7) in reference to clinical data including the
PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), DLQI (Dermatology Life Quality
Index), size of psoriatic plaque, thickness of psoriatic plaque, type of psoriasis, pruritus, arthralgia,
psoriatic arthritis, gender, and age of each patient.
Patient No.
Quantification of
LAMP1 in PP
(Arbitrary Unit)
Quantification of
LAMP1 in PN
(Arbitrary Unit)
Ratio
PP/
PN
PP/
NN
PN/
NN
6 56.94 20.39 2.79 5.36 1.92
7 35.33 10.36 3.41 3.33 0.98
2 30.45 16.72 1.82 2.87 1.57
3 29.17 11.28 2.59 2.75 1.06
5 16.17 15.88 1.02 1.52 1.50
4 12.63 10.60 1.19 1.19 1.00
1 12.49 4.97 2.51 1.18 0.47
Investigation into the association of the changes in LAMP1 expression in human skin specimens
with clinical parameters revealed a subtle positive relationship in the examined patients (Tables 1 and 2).
Noteworthy, however, is the fact that patients nos. 6 and 7, characterized by high PASI (Psoriasis Area
and Severity Index), BSA (Body Surface Area), and DLQI (Dermatology Life Quality Index) indices
(for patient no. 6 with modest severity of disease: PASI 9.6, BSA 21%, and DLQI 19; and for patient
no. 7 with mild severity of psoriasis: PASI 13.2, BSA 13%, and DLQI 16), had the highest LAMP1
expression in both the PP and PN samples among all those tested. Moreover, these two patients had
the highest ratios (2.8, 5.4, and 1.9 for patient no. 6 and 3.4, 3.3, and 1.0 for patient no. 7, respectively)
of PP vs. PN, PP vs. NN, and PN vs. NN among all those studied (Table 2).
2.5. Deregulated Gene Expression Profile in Cellular and Biopsy Tissue Material
For compilation of the data obtained from the in vitro model and the results of gene expression
in situ (i.e., skin tissue), the expression profile of 17 genes, i.e., genes of the microphthalmia family
(MiT family) of transcription factors (MITF, TFE3, TFEB and TFEC), lysosomal marker genes and
those encoding factors that control the lysosomal biogenesis process (LAMP1, MCOLN1, MTORC1,
PPP3CA and PPP3CB), and genes encoding lysosomal enzymes (ASAH, GLA, GM2A, HPSE, HYAL4,
PSAP, SMPD1 and SPHK1), were compared among the proinflammatory cytokine (“cytokine mix”)
activated HaCaT cells cultured in medium containing a Ca2+ concentration ≤0.1 mM, the non-activated
HaCaT cell control cultured in medium containing 2 mM Ca2+, and the PP vs. NN and PN vs. NN
skin tissue from psoriasis patients (psoriasis patients 8 to 18) (Figure 5). Only the genes for which the
expression was changed in all biological replicates were considered. The gene expression profile of
the HaCaT cells with “psoriasis-like” inflammation in relation to skin tissue (both PP and PN) shows
that the only common up-regulated gene (fold change, FC ≥ 1.3) was GM2A. In addition, increased
expression of the MTORC1 gene was seen only in activated HaCaT cells and in 73% of PP and 91% of
PN skin samples (Figure S1). There were no common down-regulated genes in the HaCaT cells with
“psoriasis-like” inflammation and skin specimens. Notably, the activity of six genes was decreased
in HaCaT keratinocytes: HYAL4, LAMP1, MCOLN1, MITF, PSAP, and SPHK1. Comparison of the
expression patterns between PP and PN skin samples showed a reduction in the activity of the PPP3CB,
TFEB, and TFEC genes. Down-regulation of the TFE3 gene was unique to PP skin samples, while
decreased expression of the PPP3CA gene was characteristic of PN skin tissue.
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Figure 5. Genes with changes in expression identified via real-time qRT-PCR (0.7≥FC≥ 1.3) in the HaCaT
cells with “psoriasis-like” inflammation and skin specimens of psoriasis patients 8 to 18, respectively,
with the corresponding overlap between the datasets. The number in each triangle represents the
amount of up- and down-regulated genes in the different comparisons: “cytokine mix”-activated
HaCaT cells cultured in medium containing a Ca2+ concentration ≤0.1 mM vs. non-activated HaCaT
cell control cultured in medium containing 2 mM Ca2+ (orange triangle); PP vs. NN skin (blue triangle);
and PN vs. NN skin (green triangle). PP—psoriatic plaque; PN—psoriatic normal; NN—non-psoriatic
normal (from healthy individuals 5 to 15).
2.5.1. Modulated Transcript Level in the Human Epithelial Cell Model of HaCaT Keratinocytes with
“Psoriasis-Like” Inflammation
Comparison of the human epithelial cell line HaCaT with “psoriasis-like” inflammation phenotype
with control keratinocytes cultured in medium containing a low concentration of Ca2+ ions (≤0.1 mM)
showed no significant changes in gene expression, with the exception of HYAL4, PSAP (down-regulated),
and SPHK1 (up-regulated). Keratinocytes cultured in medium containing a high concentration of Ca2+
ions (2 mM) mimics the normal differentiated keratinocyte phenotype, which is a more appropriate
control for the “psoriasis-like” cell inflammation state (Table 3). Based on this comparison, decreased
expression of the MITF, TFEB, and TFEC genes was observed in psoriatically activated keratinocytes,
while the FC for the TFE3 gene remained unchanged. Interestingly, expression of the TFEB inhibitory
protein, MTORC1, was reduced, and the level of MCOLN1 mRNA, which is involved in the opposing
mechanism, i.e., nuclear translocation and activation of TFEB, was increased. This could result in the
down-regulation of the LAMP1 gene, although the level of genes encoding the calcineurin subunits
(PPP3CA and PPP3CB) remained unchanged. The quantitative changes in lysosomes (reduction
in the LAMP1 marker) may result in the down-regulation of lysosomal enzymes or their cofactors.
The exceptions were the GLA, HPSE, and SMPD1 genes (unchanged, 1.3 ≥ FC ≥ 0.7) and GM2A
(increased expression). Importantly, down-regulation of IVL expression (a marker for early keratinocyte
differentiation) indicates that the cells remained immature, and up-regulation of the S100A7 and
S100A9 genes proves that the inflammatory response was induced, which is characteristic of the
psoriatic phenotype.
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Table 3. Real-time qRT-PCR verification of selected genes related to the microphthalmia family (MiT family) (Panel A: MITF, TFE3, TFEB, and TFEC); lysosomal
marker genes and those encoding factors that control the lysosomal biogenesis process (Panel B: LAMP1, MCOLN1, MTORC1, PPP3CA, and PPP3CB); genes encoding
lysosomal enzymes (Panel C: ASAH, GLA, GM2A, HPSE, HYAL4, PSAP, SMPD1, and SPHK1); and selected markers for psoriasis (IVL, S100A7, and S100A9) in the
human epithelial cell model of HaCaT cells with “psoriasis-like” inflammation. The relative mRNA expression levels were determined against TBP (TATA-Box
Binding Protein) in “cytokine mix”-activated HaCaT cells cultured in medium containing Ca2+ ≤ 0.1 mM vs. the non-activated HaCaT cell control cultured in medium
containing either ≤0.1 or 2 mM Ca2+, and the relative quantitation was calculated using 2−∆∆Ct (FC—fold change). Bold font signifies a change in the expression
level (≥1.3 and ≤0.7, respectively). Data represent the mean values ± standard deviation (SD) from n = 3; the non-activated HaCaT cell control cultured in medium
containing a Ca2+ concentration ≤0.1; “cytokine mix”-activated HaCaT cells cultured in medium containing 2 mM Ca2+; and the non-activated HaCaT cell control
cultured in medium containing 2 mM Ca2+.
Type of Group Gene
FC SD FC SD
“Cytokine Mix”-Activated HaCaT at Ca2+ ≤ 0.1 mM vs.
Non-Activated HaCaT Control at Ca2+ ≤ 0.1 mM
“Cytokine Mix”-Activated HaCaT at Ca2+ ≤ 0.1 mM vs.
Non-Activated HaCaT Control at 2 mM Ca2+
A
MiT family transcription factors
MITF 0.83 ±0.13 0.67 ±0.01
TFE3 1.06 ±0.05 1.02 ±0.05
TFEB 0.87 ±0.02 0.74 ±0.02
TFEC 0.91 ±0.02 0.71 ±0.01
B
Lysosomal marker and genes encoding factors that control the
lysosomal biogenesis process
LAMP1 1.05 ±0.05 0.19 ±0.01
MCOLN1 0.83 ±0.02 0.43 ±0.01
MTORC1 0.82 ±0.05 4.03 ±0.25
PPP3CA 0.98 ±0.04 1.17 ±0.05
PPP3CB 0.96 ±0.03 1.05 ±0.03
C
Lysosomal enzymes
ASAH 0.83 ±0.02 0.6 ±0.02
GLA 1.11 ±0.07 1.12 ±0.07
GM2A 1.12 ±0.07 69.81 ±4.69
HPSE 0.76 ±0.04 0.76 ±0.05
HYAL4 0.64 ±0.14 0.01 ±0.00
PSAP 0.74 ±0.09 0.58 ±0.07
SMPD1 0.83 ±0.02 0.95 ±0.03
SPHK1 1.44 ±0.14 0.65 ±0.06
Selected markers for psoriasis
IVL 1.64 ±0.98 0.32 ±0.02
S100A7 1.35 ±0.06 1.68 ±0.08
S100A9 16.23 ±0.48 45.27 ±1.31
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2.5.2. Changes in Gene Activity in Human Skin Specimens
Gene expression studies included 17 genes in 11 psoriasis patients numbered from 8 to 18 (both in
PP and PN skin tissue) and 11 healthy individuals numbered from 5 to 15 (NN skin tissue). All the
tested genes were differentially expressed (0.7 ≥ FC ≥ 1.3). A summary of the values and percentage
distribution pattern is listed in Table S1 and Figure S1.
The present study shows that the activity of the TFE3, TFEB, TFEC, PPP3CB, ASAH, and SMPD1
genes was strongly decreased in psoriatic skin (PP) as compared with non-psoriatic normal skin
(NN) in all patients regardless of clinical data (Figure 6), while the GM2A and HPSE genes were
up-regulated in the same patients. Furthermore, a reduction in the activity of the TFEB, TFEC, PPP3CA,
and PPP3CB genes and an increase in GM2A gene activity were observed in psoriatic normal skin (PN)
as compared with non-psoriatic normal skin (NN) in all patients. Expression of the MITF gene was
reduced in 82% of PP and 91% of PN skin specimens. Notably, the ASAH and SMPD1 genes, encoding
key enzymes for ceramide formation, were up-regulated in PN skin specimens (for 82% and 91% of
patients, respectively), but down-regulated in PP skin specimens in all patients. The SPHK1 mRNA
level pattern was identical in PP and PN skin specimens, i.e., up-regulated in 64%, down-regulated in
18%, and unchanged in 18% of patients). Interestingly, the GM2A and GLA genes, encoding enzymes
necessary for further conversion of ceramides, were increased in both PP and PN skin specimens, while
expression of the PSAP gene was modulated differentially. The HPSE gene was overexpressed in 100%
PP and 91% PN skin specimens, while up-regulation of the HYAL4 gene was unique to PP skin tissue.
For the majority of patients (both PP and PN skin specimens), the MTORC1 gene was overexpressed,
while the PPP3CA and PPP3CB genes were down-regulated, which may result in decreased expression
of genes belonging to the MiT family. Despite this, the LAMP1 and MCOLN1 genes had high FCs
(in 82% of patients, including PP and PN skin), which may indicate that the number of lysosomes was
increased but their biogenesis was independent of the MiT family. A comparable expression profile
for PP vs. NN and PN vs. NN demonstrates that the above changes occur prior to the onset of the
characteristic disease phenotype.
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TFE3, TFEB, and TFEC); lysosomal marker genes and those encoding factors that control the
lysosomal biogenesis process (B: LAMP1, MCOLN1, MTORC1, PPP3CA, and PPP3CB); and genes
encoding lysosomal enzymes (C: ASAH, GLA, GM2A, HPSE, HYAL4, PSAP, SMPD1, and SPHK1)
in skin specimens. The relative mRNA expression levels were determined against that of GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), and the relative quantitation was calculated using
2−∆∆Ct and compared between each group (PP—psoriatic plaque vs. NN—non-psoriatic normal,
PN—psoriatic normal vs. NN, and PP vs. PN). Scat er plots showing the rel tive expression levels of
genes, each with number f patients n = 11 (psoriasis patients 8 to 18) for PP/PN and n = 11 (healthy
individuals 5 to 15 as a control) for NN.
3. Discussion
The involvement and specific role of lysosomes and their components in the maintenance of
cellular architecture is already well-documented in scientific reports on health and disease [4,25,26];
however, the potential impact of lysosomal signaling on autoimmune-mediated inflammation in skin
diseases such as psoriasis (PsO) requires further verification. It appears that apart from human immune
system cells, the epidermis—composed mostly of keratinocytes—may also be an important area of
research, if only due to the proven interaction of both these cell types within a wide-range network
regulating the biological pattern of the largest and fastest-growing organ of the hu an body—the skin.
Normal epide m l maturation is ass ciat d with an incre sed number of lysosomes involved
in intracellular degradation. It is important to determine the pote tial con equences of changes
in the amount nd morphology of lysosomes and ther acidic org nelles in psoriasis, which may
be manifested, among others, in disturbed processes of apoptosis and autophagy, abnormalities
of sphingolipid and ceramide metabolism pathways, incorrect presentation of antigens by major
histocompatibility complex (MHC) class II molecules or increased transcription of genes encoding
selected proinflammatory cytokines and chemokines—processes being deregulated in this dermatosis.
A significant number of alterations at the level of a single cell, affecting the homeostasis of the whole
organism, can be largely explained by the characteristics of the action of lysosomes. They can play a key
role i the modulation of the immune response, a thus may be a po ential therapeutic target for many
inflammatory disorder , uch as rheuma o d arthritis, atopic der atitis, and psoriasis. For this reason,
in our study we undertook research on the verification of vicissitudes in the endos mal-lysosomal
system, at this stage of work in cells mimicking psoriasis (keratinocyte model of HaCaT cells with
“psoriasis-like” inflammation), with simultaneous analysis of material driven from people suffering
from this dermatosis.
Despite the many controversies surrounding the use of proper epidermal keratinocytes for in vitro
studies relevant to PsO, the most widely used human immortalized keratinocyte cell line, HaCaT, has
been employed as a cellular model to investigate hyperproliferative skin diseases [27–30]. HaCaT
keratinocytes are often used instead of primary keratinocytes (NHEK) for in vitro experiments related
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to psoriasis, since the susceptibility of primary cells to treatment may change with increasing numbers
of passages, whereas HaCaT provides an almost unlimited supply of identical cells, ensuring high
reproducibility [31]. On the other hand, it is necessary to add here that HaCaT keratinocytes are
not perfect in this sense. They have a sufficient limitation as a cellular model of psoriasis due to
their treatment with proinflammatory cytokines, which may not sufficiently increase proliferation
rate of cells. Thus, the studies of psoriasis based on HaCaT cells as an experimental model shall
take into account this important phenomenon, and if only possible, accompanied by additional tests,
e.g. using tissues taken from patients. In turn, it is also worth adding that, cultured primary human
keratinocytes are frequently employed for studies of psoriasis; however, interpretation of experimental
data may be complicated by donor to donor variability, the relatively short culture lifetime, and
variations between passages. Here, we investigated the use of HaCaT cells, a long-lived, spontaneously
immortalized human keratinocyte line which is able to differentiate in vitro, as a suitable model
to become undifferentiated cells under appropriate experimental conditions, mimicking the clinical
psoriatic situation as closely as possible. Going forward, an important issue regarding psoriasis research
is the involvement of in vivo experiments; thus, in addition to the HaCaT model with “psoriasis-like”
inflammation, skin specimens of lesioned and non-lesioned tissue were examined in comparison with
healthy control samples.
To verify the possible quantitative changes in organelles belonging to the lysosomal system among
the tested keratinocytes, fluorescence microscopy was first applied. Indeed, the data demonstrates
alterations in the cellular status at the level of lysosomal compartments and lysosome-related organelles
(LROs) (Figure 1). In all staining tests, i.e., in the presence of LysoTracker, anti-lysosomal-associated
membrane protein 1 (LAMP1) antibodies, and acridine orange (AO), an augmented level of lysosomes
in HaCaT cells with “psoriasis-like” inflammation was found relative to the non-activated HaCaT cell
control cultured in medium containing either Ca2+ ≤ 0.1 mM or 2 mM Ca2+. A similar tendency was
noticed in the immunohistochemical study of skin samples taken from psoriasis patients (Figure 4).
In the case of more than 70% of the tested patients (five of seven subjects), there was a statistically
significant increase in LAMP1 expression in psoriatic lesioned (PP) versus non-lesioned (PN) skin, as
well as in four of these five patients when PN was compared with non-psoriatic normal (NN) (Figure 4).
Interestingly, it was found that patients with the most pronounced PASI (Psoriasis Area and Severity
Index), BSA (Body Surface Area), and DLQI (Dermatology Life Quality Index) scores (patients nos.
6 and 7) had a high incidence of positive LAMP1 expression, which indicates a level of correlation
between particular clinical parameters and LAMP1 manifestation (Table 2). However, no significant
association was defined between LAMP1 expression and other clinical characteristics; nevertheless,
proper assessment was limited due to the small number of evaluated patients. These results were
confirmed by real-time qRT-PCR analysis in skin specimens (Figure 6 and Table S1). Up-regulation
of the LAMP1 gene (fold change, FC ≥ 1.3) was observed in 82% of psoriatic patients, including PP
and PN skin specimens. However, in contrast to our results obtained in skin sections and the data
of LAMP1 expression detected in HaCaT cells (Transcripts Per Million, TPM: 298.9) [32], there was
down-regulation of LAMP1 in our HaCaT model with “psoriasis-like” inflammation (Table 3). Since
the presence of LAMP1 is noticeable in the same cells in culture, as evidenced by immunofluorescence,
the effect on LAMP1 mRNA expression observed in the present study suggests post-transcriptional
control of LAMP1 production in HaCaT cells. A possible explanation for the discrepancy in the
levels of LAMP1 protein and mRNA in our cultures of keratinocytes is the presence of a feedback
loop that degrades the mRNA transcript following synthesis of a large amount of protein. Moreover,
electron microscopy identified a substantially increased population of autophagosomes and a reduced
population of autolysosomes in keratinocytes with “psoriasis-like” inflammation as compared with
the control (Figure 3). There may be a mechanism that moderates or even blocks efficient fusion of
numerous lysosomes with autophagosomes in proinflammatory cytokine-treated HaCaT cells, resulting
in a reduction in the autolysosome population in these cells. On the other hand, it is known from the
literature that lysosomes and lysosome-like compartments are involved in epidermal differentiation,
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the stage of cell maturation that is impaired in PsO [33–36]. The role of lysosomes in cell differentiation
is supported by several studies performed in various cell types including keratinocytes [36]. In the
normal human epidermis, lysosomes in keratinocytes, revealed by LAMP1 staining, were mainly
observed in the granular layer, perhaps as lamellar granules involved in the keratinization and
desquamation processes, whereas in cultured keratinocytes, lysosomes were abundant in subconfluent
conditions. LAMP1 expression is elevated in normal proliferating keratinocytes, while it is significantly
down-regulated upon entering the differentiation stage. Furthermore, maturing keratinocytes reveal
deregulated lysosomal biogenesis and function, which in turn may be linked to the action of the
microphthalmia family (MiT family) transcription factors. Recent studies have led to the identification of
a lysosome signaling pathway and gene network that regulate cellular clearance and metabolism [25,26].
Using this approach, it was discovered that lysosome status is coordinated by the transcription factor
EB (TFEB), a member of the MiT family, and its translocation from the cytosol to the nucleus [6]. Since
TFEB plays a fundamental role in cell homeostasis and globally modulated lysosomal function, an
investigation into the endogenous TFEB subcellular localization in our in vitro model was carried
out (Figure 2). Surprisingly, rather than being due to proinflammatory cytokine stimulation, the
cytosol-to-nucleus shuttling of TFEB was calcium-dependent.
It is worth mentioning that RNA expression profiling studies, carried out to analyze differentially
expressed genes (DEGs), revealed a number of changes in the expression of genes specific to lysosomal
function or other signaling pathways mediating the pathogenesis of PsO [12,37,38]. Numerous genes
associated with lysosomes are termed coordinated lysosomal expression and regulation (CLEAR), the
elements of which are recognized by the MiT family factors, promoting gene transcription. With the
exception of TFEB, the MiT family of transcription factors include MITF, involved in melanogenesis;
TFE3, which promotes the expression of genes downstream of transforming growth factor beta (TGFβ)
signaling; and TFEC, which plays a role in cell survival, growth, and differentiation. With respect
to lysosomal metabolism studies in this field, an interesting observation is the dysregulation of
sphingolipid metabolism, in particular alterations in ceramides being a central hub of the sphingolipid
pathway, in inflammatory skin diseases such as psoriasis and atopic dermatitis [39]. Sphingolipids, as
bioactive molecules with a putative involvement in inflammation, play an important role in epidermal
signaling [40]. A wide range of chemical structures of sphingolipids (giving various types of these
compounds, i.e., ceramides, ceramide-1-phosphate, sphingomyelin, sphingosine-1-phosphate, or
glycosphingolipids) is reflected in their function in the skin, specifically in proliferation signaling,
survival and apoptotic processes, cell migration and adhesion, or angiogenesis. The highest percentage
(almost 50%) of all sphingolipids in the epidermis are ceramides; however, this quantity is much
lower in psoriatic plaque skin, which through its anti-apoptotic effect, contributes to the excessive
proliferation of keratinocytes [40,41]. Furthermore, quantitative changes of sphingolipids can cause
increased transepidermal water loss (TEWL) and epidermal barrier dysfunction. Moreover, there is
altered sphingosine conversion in psoriatic patients’ skin, in which the level of the proinflammatory
and prosurvival sphingosine-1-phosphate form is more common. In the present study, up-regulation
of the ASAH and SMPD1 genes (encoding enzymes necessary for the production of ceramide) was
observed in PN skin specimens, while down-regulation was observed in PP specimens (Figure 6 and
Figure S1), which may indicate quantitative disturbances (decreased amounts) in ceramides, resulting
in a lack of differentiation and excessive proliferation of keratinocytes, suppression of the apoptotic
process, and finally impairment of the skin barrier. Increased SPHK1 activity in PP tissue sections may
additionally result in excessive synthesis of sphingosine-1-phosphate, contributing to the production
of tumor necrosis factor alpha (TNF-α), activation of the nuclear factor kappa light chain enhancer of
activated B cells (NF-κB) pathway, or secretion of interleukin 8 (IL-8).
On the other hand, the function of the sphingosine form is calcium release from acidic stores,
essential for TFEB translocation, which in turn is mediated by mucolipin-1 (MCOLN1) and calcineurin.
This mechanism results in the biogenesis of lysosomes and the activation of autophagy processes,
which are not observed in psoriatic epidermis [42–44]. The MTORC1 gene was up-regulated in the
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majority of psoriasis patients in the present study, while the opposite genes, PPP3CA and PPP3CB,
encoding calcineurin subunits, were down-regulated, which consequently led to reduced mRNA
belonging to the MiT family. Interestingly, there was both an up-regulation of LAMP1 gene activity
and an elevated level of signaling protein in psoriatic skin tissue, which may indicate that the overall
number of lysosomes is increased in PP skin, but their biogenesis process dependent on the MiT family
transcription factors is inhibited. Therefore, endoplasmic reticulum (ER) stress may be a potential
cause of the formation of lysosomes [34].
It must be mentioned that there are certain limitations faced by the present study. For instance,
the use of a restricted number of samples may introduce bias to this study; hence, future investigations
including larger sample sizes are necessary to confirm the results of the present exploration. A series
of further in vitro and in vivo experiments are in progress. We anticipate that our research group will
report related studies to illustrate the molecular mechanisms involved in the regulation of lysosome
signaling, even considering it as a potential target for therapeutic intervention in serious inflammatory
skin diseases such as psoriasis.
4. Materials and Methods
4.1. Cell Line, Culture Media, and Reagents
Spontaneously transformed keratinocytes from histologically normal skin (HaCaT cell line) were
purchased from the CLS Cell Lines Service GmbH (Eppelheim, Germany) [45]. HaCaT cells from
passage 38−42 were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Thermo
Fisher Scientific) and 1% antibiotic/antimycotic solution (Gibco, Thermo Fisher Scientific) at 37 ◦C in a
humidified atmosphere containing 5% carbon dioxide (CO2).
4.2. Two-Dimensional (2D) Engineered Skin Psoriatic Model
HaCaT cells were cultured to 80% confluence in 25-cm2 flasks containing DMEM supplemented
with 10% FBS and 1% antibiotic/antimycotic solution. Subsequently, cells were enzymatically digested
using 0.025% trypsin−0.01% EDTA and seeded on 6-well plates at a density of 4 × 105 cells/well
in defined serum-free keratinocyte medium (Keratinocyte-SFM, Gibco, Thermo Fisher Scientific)
supplemented with bovine pituitary extract (BPE) and epidermal growth factor (EGF) (Gibco, Thermo
Fisher Scientific). Following a 24-h incubation, the medium was changed to Keratinocyte-SFM
without growth supplements for a further 16 h. Cells were then stimulated with a combination of a
proinflammatory cytokines (“cytokine mix”): interleukin 1 alpha (IL-1α), interleukin 17A (IL-17A),
interleukin 22 (IL-22), oncostatin M (OSM), and tumor necrosis factor-α (TNF-α) (Gibco, Thermo Fisher
Scientific) at a concentration of 2 ng/mL each constituent. For better evaluation of the results, two
control conditions were carried out: (1) Untreated cells cultured in medium with a low concentration
of calcium ions (≤0.1 mM) (Keratinocyte-SFM, Gibco, Thermo Fisher Scientific); and, (2) untreated cells
cultured in medium with a high concentration of calcium ions (addition of 2 mM calcium chloride for
24 h) (Keratinocyte-SFM, Gibco, Thermo Fisher Scientific).
4.3. Ethical Consent and Study Design Regarding Skin Biopsies
The in vivo material, i.e., the skin tissue, was collected from 18 psoriasis patients (numbered from
1 to 18), i.e.,: 7 subjects (numbered from 1 to 7) for the immunohistochemistry studies and 11 subjects
(numbered from 8 to 18) for the gene expression analysis; and 15 healthy individuals as a control
(numbered from 1 to 15), i.e., 4 subjects (numbered from 1 to 4) for the immunohistochemistry studies
and 11 subjects (numbered from 5 to 15) for the gene expression analysis, and the study was assembled
within the framework of our collaboration with the Department of Dermatology, Venerology, and
Allergology at the Medical University of Gdan´sk. Signed informed consent was obtained from all
subjects under protocols approved by the Independent BioEthics Committee of the Medical University
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of Gdan´sk (NKBBN/161/2017 and NKBBN/161-634/2018). Patient data were classified with respect
to gender, age, family history, BMI, and disease indicators such as PASI (Psoriasis Area and Severity
Index), BSA (Body Surface Area), and DLQI (Dermatology Life Quality Index).
4.4. Determination of the Localization and Quantitative Changes in the Lysosomal Organelles via
Fluorescence Microscopy
To visualize the acidophilic cell compartments, LAMP1 and acridine orange staining were used.
Lysosomal membrane integrity and maintenance of the lysosomal−cytosolic pH gradient was assessed
using acridine orange (AO) relocation techniques.
An equal number of HaCaT cells (1 × 105 cells/well) was seeded on glass slides (Millicell EZ
SLIDE 8-well glass, Millipore, Burlington, MA, USA) in supplemented DMEM (Gibco, Thermo
Fisher Scientific) and cultured for 24 h. The culture medium was replaced with Keratinocyte-SFM
(Gibco, Thermo Fisher Scientific) supplemented with BPE and EGF (Gibco, Thermo Fisher Scientific).
Following a 6-h incubation, cells were cultured in Keratinocyte-SFM without growth supplements
for a further 16 h. For subsequent experiments, cells were stimulated for 24 h with a combination
of proinflammatory “cytokine mix”: IL-1α, IL-17A, IL-22, OSM, and TNF-α (Gibco, Thermo Fisher
Scientific) at a concentration of 2 ng/mL each constituent. The control cells were left unstimulated in
Keratinocyte-SFM containing a low concentration of calcium ions (≤0.1 mM) (Gibco, Thermo Fisher
Scientific). An additional control without the cytokine mixture but with 2 mM Ca2+ was applied to
simulate conditions prone to keratinocyte differentiation.
Images were captured immediately using a Leica DMI4000 B microscope (Leica, Wetzlar, Germany)
and the LAS X software (ver 3.0.16120.2, Leica, Wetzlar, Germany) at 100×magnification, from randomly
selected ten microscopic fields containing 50–100 cells, each from three independent experiments
(n = 3).
4.4.1. LAMP1 Detection Using a Specific Fluorescently Labelled Antibody
To assess the lysosomal number and distribution via LAMP1 staining, proinflammatory
cytokine-stimulated HaCaT cells were fixed with 4% paraformaldehyde (PFA) for 10 min at room
temperature (RT) and subsequently permeabilized with 0.1% Triton X-100 for 15 min at RT. Cells were
then blocked with 3% BSA in PBS + 0.1% Tween for 1 h at 4 ◦C. Immunostaining was performed by
overnight incubation with a LAMP1 primary antibody (#9091, Cell Signaling, Leiden, Netherlands;
1:200) in blocking solution at 4 ◦C. The following day, cells were washed three times with PBS and
incubated with a secondary antibody (anti-rabbit IgG (H + L), F(ab′)2 fragment, Alexa Fluor® 594
Conjugate; #8889, Cell Signaling, Leiden, Netherlands; 1:1000) in blocking solution for 1 h at 4 ◦C.
After three washes with PBS, coverslips were mounted in SlowFade™ Diamond Antifade Mountant
with DAPI (Invitrogen, Thermo Fisher Scientific). Each treatment was analyzed in triplicate in three
independent experiments.
4.4.2. Visualization of Acidic Organelles Using Acridine Orange (AO) Staining
Since AO is a metachromatic fluorophore that emits red fluorescence at high acidic pH (intact
lysosome) and green fluorescence at low acidic pH (cytosol and nucleus), lysosomal membrane
destabilization was monitored as a decrease in granular red fluorescence or an increase in diffuse
cytoplasmic green fluorescence. Chloroquine (CQ), which raises lysosomal pH, was used as a positive
control. Granular red puncta were also indicators of lysosome number.
HaCaT cells cultured on glass slides were treated with 50 µM chloroquine sulphate (Sigma-Aldrich,
St. Louis, MO, USA) for 24 h in conjunction with proinflammatory cytokine stimulation. After three
washes with PBS, cells were incubated with 50 nM AO in Keratinocyte-SFM (Gibco, Thermo Fisher
Scientific) without growth supplements, for 15 min at 37 ◦C, followed by three further PBS washes.
Each treatment was performed in triplicate, with and without CQ, in three independent experiments.
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4.4.3. Quantitation of Acidic Organelles Using AO Staining
AO can be used to stain and count acidic organelles such as endosomes, lysosomes, and
autolysosomes. Upon blue light excitation (485 nm) at low pH (inside organelles), it emits orange
fluorescence (peak at 620 nm) and green fluorescence (peak at 530 nm) in the cytoplasm. A ratio of 530/620
was adopted to estimate the cytoplasmic to lysosomal area in proinflammatory cytokine-stimulated
HaCaT cells.
A total of 5 × 105/well keratinocytes were seeded on 96-well plates containing supplemented
DMEM (Gibco, Thermo Fisher Scientific) and cultured for 24 h. Subsequently, the culture medium was
replaced with Keratinocyte-SFM (Gibco, Thermo Fisher Scientific) supplemented with BPE and EGF
(Gibco, Thermo Fisher Scientific). Following a 6-h incubation, cells were cultured in Keratinocyte-SFM
without growth supplements for a further 16 h. For subsequent experiments, cells were stimulated for
24 h with a combination of proinflammatory “cytokine mix”: IL-1α, IL-17A, IL-22, OSM, and TNF-α
(Gibco, Thermo Fisher Scientific) at a concentration of 2 ng/mL each constituent. The control cells
were left unstimulated in Keratinocyte-SFM containing a low concentration of calcium ions (≤0.1 mM)
(Gibco, Thermo Fisher Scientific). An additional control without the cytokine mix but with 2 mM Ca2+
was applied to simulate conditions prone to keratinocyte differentiation.
After treatment, cells were washed three times with PBS and incubated with 50 nM AO in
Keratinocyte-SFM (Gibco, Thermo Fisher Scientific) without growth supplements for 15 min at 37 ◦C,
followed by three further washes with PBS. Fluorescence quantitation was performed using an
EnSpire Multimode Fluorescence Plate Reader (Perkin Elmer, Waltham, MA, USA). Each treatment
was performed in 20 wells in three independent experiments.
4.4.4. Determination of the Subcellular Localization of Transcription Factor EB (TFEB)
To analyze the proinflammatory effect on TFEB nuclear translocation, cytokine-stimulated HaCaT
cells were fixed with 4% PFA for 10 min at RT. For endogenous TFEB staining, cells were permeabilized
with 0.1% Triton X-100 for 15 min at RT, followed by blocking with 3% BSA in PBS + 0.1% Tween for
1 h at 4 ◦C. Immunostaining was performed by overnight incubation with a TFEB primary antibody
(#4240, Cell Signaling, Leiden, Netherlands; 1:1000) in blocking solution at 4 ◦C. The following day,
cells were washed three times with PBS, and incubated for 1 h with a goat anti-rabbit IgG Alexa Fluor
488 secondary antibody (#A-11034, Invitrogen, Thermo Fisher Scientific,; 1:500) in blocking solution
at 4 ◦C. Following an additional three washes with PBS, coverslips were mounted in SlowFade™
Diamond Antifade Mountant with DAPI (Invitrogen, Thermo Fisher Scientific). Each treatment was
analyzed in triplicate in three independent experiments. An additional control with 0.3 µM Torin 1
(MTORC1 inhibitor) was applied for the last 3 h of treatment.
4.5. Lysosomal Ultrastructure Determination Using Transmission Electron Microscopy (TEM)
To determine the effect of proinflammatory stimulation on HaCaT cellular structures, 1.5 x 105
cells/well were seeded on 12-well plates and cultured overnight. The culture medium was then
replaced with Keratinocyte-SFM (Gibco, Thermo Fisher Scientific) supplemented with BPE and EGF
(Gibco, Thermo Fisher Scientific). Following a 6-h incubation, cells were cultured in Keratinocyte-SFM
without growth supplements for a further 16 h. For subsequent experiments, cells were stimulated for
24 h with a combination of proinflammatory “cytokine mix”: IL-1α, IL-17A, IL-22, OSM, and TNF-α
(Gibco, Thermo Fisher Scientific) at a concentration of 2 ng/mL each constituent. The control cells
were left unstimulated. Following treatment, cells were washed three times with PBS, fixed with 2.5%
glutaraldehyde and subsequently with 1% osmium tetroxide and 1% potassium hexacyanoferrate
(III), and dehydrated in ethanol. Ultrasections of Epon 812 resin (Sigma-Aldrich Produktions GmbH,
Fluka, Steinheim, Germany)-embedded cells were stained with lead citrate and uranyl acetate and
examined using a transmission electron microscope (CM100, Philips, Amsterdam, Netherlands). All
photographs were taken using the iTEM program (Olympus Soft Imaging Solution, Tokyo, Japan).
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The keratinocytes had an intact membrane and visible cells structures (nucleus, mitochondria, and
lysosomes). At least 30 cells obtained from three independent cell cultures (n = 3) were examined, and
representative electron micrographs are shown (1650×magnification).
4.6. LAMP1 Evaluation Using Immunohistochemistry
Skin biopsies with a minimum diameter of 3 mm (two clippings in the study group of 7 subjects
(numbered from 1 to 7): From the psoriatic plaque and the non-lesioned skin; and one clipping in the
control group of 4 healthy individuals (numbered from 1 to 4)) were taken from the buttocks, fixed
with 4% PFA in PBS, and embedded in paraffin. Subsequently, 5 µm-thick sections were mounted on
Superfrost adhesive slides (Fisher Scientific, Hampton, NH, USA), and the epitopes were exposed by
boiling in a 10-mM citric acid solution (pH 6.0). Endogenous peroxidase activity was inhibited using
3% hydrogen peroxidase in methanol for 5 min. Sections were blocked with 10% goat serum/1% BSA
in PBS for 1 h and stained with mouse anti-LAMP1 (eBioH4A3, Invitrogen, Thermo Fisher Scientific;
5 µg/mL) in 1% BSA for 1 h at RT. Sections were subsequently washed in PBS and incubated with a
biotinylated goat anti-mouse IgG secondary antibody (Vector Laboratories Inc, Burlingame, CA, USA;
4 µg/mL) in 10% normal goat serum (Vector Laboratories Inc)/1% BSA in PBS for 45 min at RT. Finally,
an anti-biotin tertiary antibody (VECTASTAIN Elite ABC-Peroxidase Kit, Vector Laboratories Inc) was
added for 30 min according to the manufacturer’s instructions. The reaction was developed using DAB
substrate (Vector Laboratories Inc) according to the manufacturer’s instructions. For quantification
analysis, nickel was added to the DAB substrate to obtain black staining. A non-specific mouse IgG
was used as a control in place of the primary antibody. All comparative sections were performed at
the same time under identical conditions. Images were taken using an IX51 Olympus inverted light
microscope (Olympus, Tokyo, Japan) with a color CCD camera and the cellSens imaging software
(ver 1.12, Olympus). Comparative images were taken under the same light conditions and processed
in the same way.
Four to ten non-overlapping low power (20× magnification) fields of view were digitally
photographed from each section using an IX51 Olympus inverted light microscope (Olympus) with a
color CCD camera and the cellSens imaging software (ver 1.12, Olympus). Identical exposure settings
were used for each stain, and all photographs were taken during one session. Images were transformed
to eight-bit grey resolution and stored in a TIFF format. The ImageJ software (ver.1.8.0_112, National
Institutes of Health, Bethesda, MD, USA) was used for quantitation of LAMP1 staining. The entire
non-manipulated field of view was blinded and quantitated for each stain, whilst an unstained area
was used to determine (and subtract) background staining for each section. An average optical density
for each section and each patient was calculated, which were subsequently averaged to give a group
mean for the sample for each patient. Statistical analyses of LAMP1 expression in skin biopsies was
made by comparisons among particular paired PP vs. PN, PP vs. mean NN, and PN vs. mean NN,
and statistical differences are observed following application of a nonparametric Mann–Whitney U
test, with continuity correction (p ≤ 0.05).
4.7. RNA Processing
4.7.1. Cell Cultures
Total RNA was extracted from cells using the High Pure RNA Isolation Kit (Roche Applied
Science, Penzberg, Germany) following the manufacturer’s instructions. The quantity of each RNA
sample was evaluated using Quant-iT™ RiboGreen™ RNA Assay Kit (Invitrogen, Thermo Fisher
Scientific). In addition, the quality of each RNA sample was assessed using the RNA 6000 Nano Assay
on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The synthesis of cDNA
from an RNA template was conducted using Transcriptor First-Strand cDNA Synthesis Kit (Roche
Applied Science).
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4.7.2. Skin Specimens
Total RNA was extracted from skin biopsies of 11 psoriasis patients (numbered from 8 to 18)
and 11 control group subjects (numbered from 5 to 15) with the RNeasy Mini Kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. The quality and quantity of each RNA sample
was evaluated using the RNA 6000 Nano Assay on the Agilent 2100 Bioanalyzer (Agilent Technologies)
and Quant-iT™ RiboGreen™ RNA Assay Kit (Invitrogen, Thermo Fisher Scientific). The synthesis of
cDNA from an RNA template was conducted by Transcriptor First-Strand cDNA Synthesis Kit (Roche
Applied Science).
4.8. Real-Time Quantitative Reverse Transcription PCR Assays for mRNA Analysis (Real-Time qRT-PCR).
Real-time quantitative reverse transcription polymerase chain reaction (real-time qRT-PCR) was
carried out with the Single Tube Custom TaqMan Gene Expression Assays (Thermo Fisher Scientific)
and the LightCycler1 480 Probes Master (Roche Applied Science) using the Light Cycler 480 II
detection system (Roche Applied Science). Expression values were normalized against control genes:
GAPDH and TBP. The TaqMan probes used were as follows: ASAH (Hs00602774_m1), GAPDH
(Hs02786624_g1), GLA (Hs00609238_m1), GM2A (Hs00166197_m1), HPSE (Hs00935036_m1), HYAL4
(Hs00202177_m1), IVL (Hs00846307_s1), LAMP1 (Hs00931461_m1), MCOLN1 (Hs01100653_m1), MITF
(Hs01117294_m1), MTORC1 (Hs00234508_m1), PPP3CA (Hs00174223_m1), PPP3CB (Hs00236113_m1),
PSAP (Hs01551096_m1), S100A7 (Hs01923188_u1), S100A9 (Hs00610058_m1), SMPD1 (Hs03679346_g1),
SPHK1 (Hs00184211_m1), TBP (Hs00427620_m1), TFE3 (Hs00232406_m1), TFEB (Hs00292981_m1),
and TFEC (Hs00992838_m1). Each experiment of real-time qRT-PCR analysis was repeated at least
three times (n). In case of HaCaT cells they were biological replications and data are reported as the
mean SD with p < 0.05 considered statistically significant. For skin specimens technical repetitions
were conducted.
5. Conclusions
As a result of our work, we observed an increased number of lysosomes both in the keratinocytes
with “psoriasis-like” inflammation and in 70% of patients (their lesioned and non-lesioned psoriatic
skin compared to normal tissue). Quantitative changes of lysosomes may result in the deregulation
of selected enzymes, e.g. those involved in the ceramide conversion pathway, and thus lack of
differentiation and excessive proliferation of keratinocytes, inhibition of apoptosis and disturbed skin
barrier. Increased SPHK1 gene activity in psoriatic lesioned (PP) skin may additionally generate
excessive synthesis of sphingosine phosphate 1, resulting in the production of tumor necrosis factor
alpha (TNF-α), activation of the nuclear factor kappa light chain enhancer of activated B cells (NF-κB)
pathway or secretion of interleukin 8 (IL-8).
For most patients (both PP and non-lesioned (PN) skin) we observed upregulation of MTORC1
(transcription factor EB (TFEB) inhibitor) gene expression and downregulation of genes encoding
calcineurin subunits PPP3CA and PPP3CB (TFEB activator), which results in decreased activity of genes
encoding the microphthalmia family (MiT family) transcription factors (being responsible for lysosomes’
biogenesis). Despite this, there is an increased expression of the MCOLN and LAMP1 genes, which
may indicate: (1) An increased number of lysosomes; and (2) inhibition of the lysosomal biogenesis
process dependent on the MiT family transcription factors. Lysosomes can arise from endoplasmic
reticulum stress [34]. A similar expression profile for PP and PN vs. NN group may indicate that, the
above changes occur before the appearance of the characteristic phenotype of the disease.
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